The regenerative biostimulator that renews skin from within1-12,27

Over time, we may feel we don’t look like we used to

That our face has started to sag and our skin looks dull and tired.

Sculptra® is a regenerative treatment

The first proven regenerative biostimulator.

Sculptra® helps address multiple skin concerns1,5,15-18 while delivering progressive, natural-looking, and long-lasting results for more than 2 years.2-4,6-11

Whether you are looking for:


  • Improved skin quality for a radiant, youthful glow6,13,27
  • Renewed volume2,6,12,27
  • A lifted appearance6,14

  • 89%

    patients who reported improvement in skin firmness 2 years after treatment6

  • 91%

    patients who reported an improvement in skin radiance (glow) 2 years after treatment6

  • 86%

    of patients maintained enhanced jawline definition 2 years after treatment6

Before & After photos

Real patient, individual results may vary

 

Sculptra®

The first proven regenerative biostimulator

Sculptra® is the first proven regenerative biostimulator that helps restore the skin’s structure.1,5,6,15-19

It stimulates collagen and elastin, strengthening your skin’s foundation, increasing its healthy thickness and restoring firmness over time.2-4, 7, 11, 12-13, 20-23

“Having rejuvenated skin just made me feel happier and younger so I could get up and go. It looks natural and dewy.”

Chloe, 39 years old

Rejuvenated, firm and radiant skin lasting more than 2 years2,6,24

Stay true to you! Sculptra® works progressively by increasing your own collagen and elastin,1-4,7,11,12-13.20-23 with visible results already 1 month after treatment and that last for more than 2 years.1-2,4,6

Frequently asked questions

You will start to notice visible results already after one month.2,4,6 Sculptra® works progressively, so there will be a gradual improvement in skin firmness, radiance and volume over time.2,6,11,13,24-26

One of the best things about Sculptra® is how long it lasts. The treatment provides rejuvenated skin for more than 2 years.2,4,6

Good news—there’s minimal downtime with Sculptra®! You may experience mild bruising or bleeding, pain or tenderness, swelling, redness, or itching at the injection site, usually appearing soon after treatment. These effects are typically short-lived and resolve on their own within about a week, so most people return to their normal routine quickly¹. Always consult your healthcare practitioner for personalised advice and to discuss safety information and potential risks associated with Sculptra®.

References

  1. Sculptra® EU MDR IFU
  2. Brandt FS, et al. Aesthet Surg J. 2011;31(5):521–8.
  3. Fabi S, et al. Dermatol Surg. 2024;50:1137–42.
  4. Narins RS, et al. J Am Acad Dermatol. 2010;62(3):448–62.
  5. Widgerow A, et al. A randomized, comparative study describing the gene signatures of poly-L-lactic Acid (PLLA-SCA™) and calcium hydroxylapatite (CaHA) in the treatment of nasolabial folds. Poster, IMCAS World Congress, 1–3 Feb 2024, Paris.
  6. Fabi S, et al. Poster: Effectiveness and safety of correction of cheek wrinkles using a biostimulatory poly-L-lactic acid injectable implant—clinical study data up to 24 months. IMCAS World Congress, 26–28 Jan 2023, Paris.
  7. Huth S, et al. J Drugs Dermatol. 2024;23(4):285–8.
  8. FDA. Summary of safety and effectiveness data. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf3/ p030050s002b.pdf. Accessed (2022 Nov).
  9. Galderma. Data on file (MA-54151).
  10. Galderma. Data on file (MA-46589).
  11. Goldberg D, et al. Dermatol Surg. 2013;39(6):915–22.
  12. Valantin MA, et al. AIDS. 2003;17(17):2471–7.
  13. Bohnert K et al. Dermatol Surg. 2019; 45(5):718–24.
  14. Galderma. Data on file (MA-50526).
  15. Galderma Receives FDA Approval for New SCULPTRA® Label, Offering More Options to Aesthetic Partners. Galderma. 2021. Available from: https://www.galderma.com/news/galderma-receives-fda-approvalnew-sculptra-label-offering-more-options-aesthetic-partners [Last accessed June 2024].
  16. U.S. Patent US 7,731,758 B22(010):2010
  17. Sanofi S.r.l. DEKRA EN ISO 13485:2016 Certificate. Certificate effective since: February 2023.
  18. Zhang Y, et al. Regen Biomater 2021;8(5):rbab042.
  19. Data on file (MA-48331).
  20. Galderma. Data on file (MA-60875).
  21. Arruda S et al. J Drugs Dermatol. 2024; 23(9):729–34.
  22. Galderma. Data on file. GLI.04.US.SL.020 Clinical Study Report. Dallas, TX: Galderma Laboratories, L.P.; 2024.
  23. Hexsel D et al. Dermatol Surg. 2020; 46(8):1122–4.
  24. Fabi S, et al. Skin movement and volume changes with poly-L lactic acid (PLLA-SCA) injectable implant. Poster presented at the International Master Course on Aging Science (IMCAS) World Congress. 26–28 January 2023. Paris, France.
  25. Mest DR, Humble G. Dermatol. Surg. 2006;32(11):1336–45.
  26. Filho CDSM, et al. Surg Cosmet Dermatol. 2013;5(4):345–50.
  27. Haddad A, et, al. Utilizing the AART Methodology to maximize aesthetic treatment outcomes using poly-L-lactic acid (PILLA-SCA) for the improvement in Appearance of Cellulite – a Pilot Study. Poster presented at IMCAS. 01-03 February 2024. Paris, France.

This material refers to the product certified under Regulation (EU) 2017/745 (MDR). Legacy versions of the product remain available. For full product information and the Instructions for Use (IFU), visit: www.galderma.com/library.

Adverse events should be reported.

For the UK, Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for Yellow Card in the Google Play or Apple App Store.

For Ireland, Suspected adverse events can be reported via HPRA Pharmacovigilance, Website: www.hpra.ie; Adverse events should also be reported to Galderma (UK) Ltd, Email: medinfo.uk@galderma.com, Tel: +44 (0) 300 3035674

UKI-SCU-2600005 DOP: April 2026